Association of a brain methylation site with clinical outcomes in depression does not replicate across populations

American Journal of Psychiatry

Volumn 172, Issue 4, 2015, Pages 395-397

  Uher, Rudolf ^a   Ripke, Stephan ^a   Müller Myhsok, Bertram ^a   Lewis, Cathryn M ^a   Perlis, Roy H ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE;

DRUG SPECIFICITY; EUROPE; FALSE POSITIVE RESULT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LETTER; MAJOR DEPRESSION; META ANALYSIS (TOPIC); METHYLATION; MEXICAN AMERICAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; UNITED STATES;

EID: 84964237812     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14101348     Document Type: Letter

References (3)

1. Wong ML, Dong C, Flores DL, et al: Clinical outcomes and genomewide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans. Am J Psychiatry 2014; 171:1297-1309
2. GENDEP Investigators; MARS Investigators; STAR∗D Investigators: Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170:207-217
3. Ripke S: Ricopili: a tool for visualizing regions of interest in select GWAS data sets. http://www.broadinstitute.org/mpg/ricopili/, 2014